S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE3
Impact of Endogenous E2 on SSI and GH Rebound
- Status
- COMPLETED
- Phase
- PHASE1
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Status
- TERMINATED
- Phase
- PHASE2
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
- Status
- COMPLETED
- Phase
- PHASE2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LY3023414 in Participants With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1